Bookmark
Forward
QuickView for nesiritide (compound)
DrugBank
Identification
| Name: | Natriuretic Peptide, Brain |
|---|---|
| Name (isomeric): | DB04899 |
| Drug Type: | biotech |
| Description: | A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. |
| Synonyms: |
Natriuretic peptides B; BNP; Brain natriuretic peptide 32
|
| Brand: | Natrecor |
| Category: | Cardiac drugs |
| CAS number: | 124584-08-3 |
Pharmacology
| Indication: | For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. |
|---|---|
| Pharmacology: | Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation. In simpler terms, it promotes vasodilation, natriuresis, and diuresis. |
| Mechanism of Action: |
Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritide has been shown to relax iso...
show more » |
| Absorption: | Administration of nesiritide exhibits biphasic disposition from the plasma. |
| Biotransformation: | Nesiritide undergoes proteolytic cleavage of the peptide by endopeptidases, such as neutral endopeptidase, which are present on the vascular lumenal surface. |
| Route of elimination: | Human BNP is cleared from the circulation via the following three independent mechanisms, in order of decreasing importance: 1) binding to cell surface clearance receptors with subsequent cellular internalization and lysosomal proteolysis; 2) proteolytic cleavage of the peptide by endopeptidases, such as neutral endopeptidase, which are present on the vascular lumenal surface; and 3) renal filtration. |
| Half Life: | Approximately 18 minutes |
| Clearance: | 9.2 mL/min/k [patients with congestive heart failure receiving IV infusion] |
| Toxicity: | No data are available with respect to overdosage in humans. The expected reaction would be excessive hypotension, which should be treated with drug discontinuation or reduction and appropriate measures. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
